2010 NF Conference
2010 NF Conference
批准号:
7914710
负责人:
FILIPPO G GIANCOTTI
金额:
$4.6万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-01 至 2011-05-31
关键词:
AddressAgeAmericanAreaAttentionAwardBackBaltimoreBasic ScienceBiotechnologyCalendarCellsCellular biologyChildCitiesClinicClinicalClinical TrialsCollaborationsCommunitiesConsensusDoctor of PhilosophyEducational workshopElementsEventFaceFosteringFoundationsFundingFutureGeneticGoalsGrowthHourInternationalJournalsLinkMalignant NeoplasmsMarylandMedical GeneticsModelingNeurofibromatosesNeurofibromin 2NewsletterNursesPharmacologic SubstancePharmacotherapyPhysiciansPlant RootsPlayProfessional counselorPublicationsPublishingRecording of previous eventsReportingRequest for ApplicationsResearchResearch PersonnelRestRoleScienceSecureSignal TransductionStagingStructureTherapeuticTimeTranslational ResearchVertebral columnabstractingbasebench to bedsidecancer cellclinical caredesignlecturesmeetingsmembernervous system disorderposterspre-clinicalpublic health relevancesymposiumtherapy developmenttumortumor growthweb site
中文摘要
描述(由申请人提供):自1985年以来,儿童肿瘤基金会每年组织一次神经纤维瘤病(NF)会议。NF会议起源于一个名为“NF联盟”的小组的研讨会式聚会,现在已经发展成为公认的最大和最重要的国际NF研究人员和医生的年度聚会。来自世界各地的280名NF研究人员和临床医生参加了2009年NF会议。这一增长的主要原因是近年来在NF研究方面取得的重大进展,特别是在临床试验和药物治疗方面的进展。传统上,NF会议是一个研究信息交流和建立共识的论坛,近年来,NF会议也成为报告神经纤维瘤病临床前治疗管道和正在扩大的神经纤维瘤病临床试验领域的主要国际论坛。2010年核论坛会议以“回到未来”为主题,在结构和布局上,它在很大程度上回归了会议最初发展起来的以研讨会为基础的模式。2010年NF会议的目标是评估NF研究已经走了多远,还有哪些主要的挑战和争议。在四天的时间里,我们将在不同的会议模式中探讨这些问题。一般会议将侧重于NF的特定主题和主题,并通过顶级研究人员的演讲进行回顾,从基础研究问题到转化和临床问题。小组和圆桌会议将讨论具有挑衅性的话题,并由讨论和观众参与推动。摘要平台和海报会议的安排,给予充分的关注,更广泛的新研究,特别是年轻的研究人员。认识到本次会议在通过基金会的NF临床网络为NF临床社区提供论坛方面日益重要的作用,在主要会议之前将有一个为期一天的研讨会,针对NF临床协调员,护士和遗传咨询师。总的来说,2010年NF会议将为NF社区带来另一个全新的视角,同时仍然是NF研究和临床护理信息日历上的首要年度活动。
英文摘要
DESCRIPTION (provided by applicant): The Neurofibromatosis (NF) Conference has been organized by the Children's Tumor Foundation annually since 1985. With its roots in a workshop-style gathering of a group called the 'NF Consortium', the NF Conference has grown and is now recognized as the largest and the premier annual gathering of international NF researchers and physicians. Two-hundred and eighty NF researchers and clinicians from around the world attended the 2009 NF Conference. A major contributor to this growth has been the significant advances made in NF research in recent years and particularly the advances into clinical trials and drug therapy development. Traditionally a forum for research information exchange and consensus building, in recent years the NF Conference has also become the principal international forum for reporting on the neurofibromatosis preclinical therapeutic pipeline and the now expanding arena of neurofibromatosis clinical trials. The 2010 NF Conference is themed Back to the Future and in structure and layout it returns to a large extent to the workshop-based model from which the Conference originally evolved. The goal of the 2010 NF Conference will be to evaluate how far NF research has come, and what are the major remaining challenges and controversies. This them will be explored in a variety of session models over four days. General sessions will focus on specific topics and themes in NF and review them through presentations from top-level researchers spanning from basic research questions to translational and clinical issues. Panel and Roundtable sessions will take on provocative topics and be driven by discussion and audience participation. Abstract platform and poster sessions are laid out to give ample attention to a broader array of new research particularly to younger investigators. Recognizing the important growing role for this Conference in serving as a forum for the NF clinical community, through the Foundation's NF Clinic Network, there will be a one-day workshop preceding the main Conference session that is targeted at NF clinic coordinators, nurses and genetic counselors. Overall, it is intended that the 2010 NF Conference will bring yet another fresh perspective to the NF community at large, while remaining the premier annual event in the calendar for NF research and clinical care information.
PUBLIC HEALTH RELEVANCE: The Children's Tumor Foundation NF Conference has had a fruitful history since its inception in 1985, and it plays a lynchpin role as the premier annual gathering of researchers and clinicians in the neurofibromatosis community. The meeting is a forum for research information exchange and discussion for neurofibromatosis researchers and clinicians from around the world, and has traditionally fostered collaboration, consensus building, and advances in translational research culminating in clinical trials. Meeting attendance has doubled in recent years from 140 attendees in 2005 to 280 attendees in 2009, driven largely by an expanding clinical agenda component as the neurofibromatosis field progresses bench to bedside.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms governing metastatic dormancy and reactivation
-
批准号:9324199
-
项目类别:
-
资助金额:$96.0万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma
-
批准号:10542988
-
项目类别:
-
资助金额:$31.31万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanisms governing metastatic dormancy and reactivation
-
批准号:10227143
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanisms governing metastatic dormancy and reactivation
-
批准号:8956183
-
项目类别:
-
资助金额:$96.0万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanisms governing metastatic dormancy and reactivation
-
批准号:10474409
-
项目类别:
-
资助金额:$95.55万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma
-
批准号:10004502
-
项目类别:
-
资助金额:$18.29万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanisms governing metastatic dormancy and reactivation
-
批准号:9982048
-
项目类别:
-
资助金额:$96.0万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanisms governing metastatic dormancy and reactivation
-
批准号:10474923
-
项目类别:
-
资助金额:$96.0万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanisms governing metastatic dormancy and reactivation
-
批准号:9751221
-
项目类别:
-
资助金额:$93.12万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma
-
批准号:9028689
-
项目类别:
-
资助金额:$52.54万
-
财政年份:2016
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanisms governing metastatic reactivation of breast cancer.
-
批准号:8642161
-
项目类别:
-
资助金额:$42.74万
-
财政年份:2013
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanisms governing metastatic reactivation of breast cancer.
-
批准号:8483319
-
项目类别:
-
资助金额:$44.06万
-
财政年份:2013
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanism of Merlin-mediated contact inhibition and tumor suppression.
-
批准号:8066767
-
项目类别:
-
资助金额:$55.05万
-
财政年份:2010
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanism of Merlin-mediated contact inhibition and tumor suppression.
-
批准号:8444699
-
项目类别:
-
资助金额:$45.21万
-
财政年份:2010
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanism of Merlin-mediated contact inhibition and tumor suppression.
-
批准号:8613469
-
项目类别:
-
资助金额:$46.47万
-
财政年份:2010
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mouse Models for Tumor Progression and Maintenance
-
批准号:8063119
-
项目类别:
-
资助金额:$42.81万
-
财政年份:2010
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
Mechanism of Merlin-mediated contact inhibition and tumor suppression.
-
批准号:8225221
-
项目类别:
-
资助金额:$54.76万
-
财政年份:2010
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
INTEGRIN SIGNALING DURING BREAST TUMORIGENESIS
-
批准号:7749542
-
项目类别:
-
资助金额:$38.96万
-
财政年份:2009
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
INTEGRIN SIGNALING DURING BREAST TUMORIGENESIS
-
批准号:7584974
-
项目类别:
-
资助金额:$39.34万
-
财政年份:2009
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
INTEGRIN SIGNALING DURING BREAST TUMORIGENESIS
-
批准号:8197894
-
项目类别:
-
资助金额:$37.79万
-
财政年份:2009
-
负责人:FILIPPO G GIANCOTTI
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: